Diethylene glycol monoethyl ether (Transcutol®) displays antiproliferative properties alone and in combination with xanthines

Skin Pharmacology and Physiology

Volumn 9, Issue 1, 1996, Pages 53-59

  Levi Schaffer, Francesca ^a   Dayan, Nava ^a,b   Touitou, Elka ^b  

^a HEBREW UNIVERSITY   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Diethylene glycol monoethyl ether; Transcutol; Xanthines

Indexed keywords

ANTIMITOTIC AGENT; CAFFEINE; DIETHYLENE GLYCOL MONOETHYL ETHER; DIPROPHYLLINE; DRUG VEHICLE; THEOPHYLLINE; XANTHINE DERIVATIVE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN 3T3; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; LYMPHOMA; MASTOCYTOMA; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSORIASIS;

3T3 CELLS; ANIMALS; CELL DIVISION; CELL LINE; DERMATOLOGIC AGENTS; ETHYLENE GLYCOLS; FIBROBLASTS; HUMANS; LYMPHOMA; MAST-CELL SARCOMA; MICE; PSORIASIS; RATS; SKIN NEOPLASMS; TUMOR CELLS, CULTURED; XANTHINES;

EID: 0030029733     PISSN: 16605527     EISSN: 16605535     Source Type: Journal    
DOI: 10.1159/000211390     Document Type: Article

References (15)

1. Hori M, Satoh S, Maibach HI: Classification of percutaneous penetration enhancers: A conceptional diagram; in Bronaugh RL, Maibach IH (eds): Percutaneous Absorption. New York, Dekker, 1989, pp 197-211.
2. Moligaard B, Hoelgaard A, Bund-gaard H: Pro-drugs as drug delivery systems. XXIII. Improved dermal delivery of 5-fluorouracil through human skin via n-acyloxymethyl pro-drug derivatives. Int J Pharm 1982;12:153-162.
3. Menczel E, Touitou E: Cutaneous permeation of lipophilic molecules: Effect of enhancers; in Bronaugh RL, Maibach HI (eds): Percutaneous Absorption. New York, Dck-ker, 1989, pp 121-133.
4. Iancu L: Experimental Treatment of Psoriasis with Compounds Which Increase the Intracellular Level of cAMP; thesis MSc of Dermatology, Tel-Aviv University, 1979.
5. Iancu L, Shneur A, Cohen H: Trials with xanthine derivatives in systemic treatment of psoriasis. Dermatologica 1979;159:55-61.
6. Levi-Schaffer F, Touitou E: Xanthines inhibit 3T3 fibroblast proliferation. Skin Pharmacol 1991;4: 286-290.
7. Touitou E, Levi-Schaffer F, Shaco-Ezra N, Ben-Yossef R, Fabin B: Enhanced permeation of theophylline through the skin and its effect on fibroblast proliferation. Int J Pharm 1991;20:159-166.
8. Touitou E, Levi-Schaffer F, Dayan N, Alhaique F, Riccicri F: Modulation of caffeine skin delivery by carrier design: Liposomes versus permeation enhancers. Int J Pharm 1994;103:131-136.
9. Touitou E, Shaco-Ezra N, Dayan N, Jushynski M, Rafaeloff R, Azoury R: Dyphylline liposomes for delivery to the skin. J Pharm Sci 1992;81: 131-134.
10. Data sheet. Gattcfosse.
11. Voorhees JJ: Commentary: Cyclic adenosine monophosphate regulation of normal and psoriatic epidermis. Arch Dermatol 1982; 118:869-874.
12. Rang HP, Dale MM: Pharmacology, ed 2. Edinburgh. Churchill Livingstone, 1991, vol 228, pp 40-41.
13. Shukla AJ, Mahashabde S: Novel uses of gelucres and transcutol in drug formulation. Gattcfosse, 1988, pp 55-60.
14. Ritschel WA, Hussain AS: In vitro skin penetration of griseofulvin in rat and human skin from ointment dosage form. Arzneimittelfor-schung/Drug Res 1988;38:1630-1632.
15. Touitou E, Levi-Schaffer F: Patent pending. 1993.